Meeting
2023 ASCO Annual Meeting
Mortality rate and social disparity trends with tyrosine kinase inhibitory availability in chronic myelogenous leukemia: An analysis in the US from 1999 to 2020.
Authors
Tony Varughese
Hackensack University Medical Center, Hackensack, NJ
Tony Varughese , Jamie Koprivnikar
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Chronic Leukemia—CML
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 7055)
DOI
10.1200/JCO.2023.41.16_suppl.7055
Abstract #
7055
Poster Bd #
185
Abstract Disclosures
Similar Posters
First Author: Ronald J. Rieder
Poster
2018 ASCO Annual Meeting
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors (TKIs) in patients (pts) with Philadelphia chromosome–positive (Ph+) leukemia: Phase 1/2 study update.
First Author: Carlo Gambacorti-Passerini
Poster
2013 ASCO Annual Meeting
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).
First Author: Lei Chen
Poster
2012 ASCO Annual Meeting
Efficacy and safety of bosutinib (BOS) for Philadelphia chromosome–positive (Ph+) leukemia in older versus younger patients (pts).
First Author: Tim H. Brummendorf